The global HIV drugs market size surpassed USD 34.10 billion in 2023 and is estimated to increase from USD 36.22 billion in 2024 to approximately USD 66.16 billion by 2034. It is projected to grow at a CAGR of 6.21% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on HIV Drugs Market
5.1. COVID-19 Landscape: HIV Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global HIV Drugs Market, By Medication Class
8.1. HIV Drugs Market Revenue and Volume, By Medication Class, 2024-2034
8.1.1 Multi-class Combination Drugs
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Entry & Fusion Inhibitors
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Protease Inhibitors (PIs)
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. Integrase Inhibitors
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
8.1.7. Coreceptor Antagonists
8.1.7.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global HIV Drugs Market, By Drug Type
9.1. HIV Drugs Market Revenue and Volume, By Drug Type, 2024-2034
9.1.1. Branded Drugs
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Generic Drugs
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global HIV Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.1.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.2.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.3.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.4.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.5.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Medication Class (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
Chapter 11. Company Profiles
11.1. AbbVie Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Boehringer Ingelheim International GmbH
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bristol-Myers Squibb Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cipla Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Genentech, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Gilead Sciences, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Merck & Co., Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. ViiV Healthcare
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample